• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of cancer care >Cost‐effectiveness analysis of fulvestrant versus anastrozole as first‐line treatment for hormone receptor‐positive advanced breast cancer
【24h】

Cost‐effectiveness analysis of fulvestrant versus anastrozole as first‐line treatment for hormone receptor‐positive advanced breast cancer

机译：氟斯特朗特与阿斯特罗兹孔作为一种激素受体 - 阳性晚期乳腺癌的初始治疗的成本效益分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Although recent studies demonstrated that fulvestrant is superior to anastrozole as first‐line treatment for hormone receptor ( HR )‐positive advanced breast cancer, the cost‐effectiveness of fulvestrant versus anastrozole remained uncertain. Thus, the current study aimed to evaluate the cost‐effectiveness of fulvestrant compared with anastrozole in the first‐line setting. A Markov model consisting of three health states (stable, progressive and dead) was constructed to simulate a hypothetical cohort of patients with HR ‐positive advanced breast cancer. Costs were calculated from a Chinese societal perspective. Health outcomes were measured in quality‐adjusted life‐year ( QALY ). The incremental cost‐effectiveness ratio ( ICER ) was expressed as incremental cost per QALY gained. Model results suggested that fulvestrant provides an additional effectiveness gain of 0.11 QALY s at an incremental cost of $32,654 compared with anastrozole, resulting in an ICER of $296,855/ QALY exceeding the willingness‐to‐pay threshold of $23,700/ QALY . Hence, fulvestrant is not a cost‐effective strategy compared with anastrozole as first‐line treatment for HR ‐positive advanced breast cancer.
机译：摘要虽然最近的研究表明，氟斯特提优于阿斯特罗兹罗罗斯作为激素受体（HR） - 阳性晚期乳腺癌的一线治疗，但富腊肠与Anstrozole的成本效益仍然不确定。因此，目前的研究旨在评估氟斯特朗特的成本效益与第一线设置中的Anstrozole相比。建立了由三种健康状态（稳定，渐进和死亡）组成的马尔可夫模型，以模拟HR阳性晚期乳腺癌患者的假想队列。从中国社会角度计算成本。在质量调整的寿命年（QALY）中测量了健康结果。增量成本效益比（ICER）表示为每QALY获得的增量成本。模型结果表明，与阿斯特罗兹洛州相比，普瑞斯特将额外的有效性增益为0.11 QALY S，以32,654美元的增量成本为32,654美元，导致超过296,855美元/ QALY的标语，超过23,700美元/ QALY的愿意支付门槛。因此，与Anastrozole作为HR-xPositive晚期乳腺癌的一线治疗，氟斯特提不是一种成本效益的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号